Yonghong Huan, MD
Nephrology · Philadelphia, PANPI 1568525269
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,182 of the $6,045 with a category attached, or 69.2%. Otsuka America Pharmaceutical, Inc. accounts for 71.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $4,873 and has fallen 81.7% since, to $891 in 2025.
Across 23 payments — averaging $262.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$4K
- AstraZeneca$609
- Bayer$215
- Fresenius USA Marketing, Inc.$179
- Stemline Therapeutics Inc.$131
- Vantive US Healthcare LLC$128
- plus $487 from 5 others
Across 2 payments — averaging $13,814 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$24K
- Ironwood Pharmaceuticals, Inc$4K
What the payments were for
- Consulting fees$4,18269%
- Travel & lodging$1092%
- Food & beverage$1,74429%
- Education$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $4,296 |
| AstraZeneca | 5 | $609 |
| Bayer | 2 | $215 |
| Fresenius USA Marketing, Inc. | 4 | $179 |
| Stemline Therapeutics Inc. | 1 | $131 |
| Vantive US Healthcare LLC | 1 | $128 |
| Amgen | 1 | $125 |
| Beigene USA, Inc. | 1 | $125 |
| Baxter Healthcare | 1 | $118 |
| Calliditas Therapeutics US Inc. | 1 | $113 |
| Travere Therapeutics, Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,045 in reported general payments places this provider in the 85th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Thiola EcTiopronin | 22 | $338,658 |
| VelphoroSucroferric Oxyhydroxide | 24 | $54,119 |
| XphozahTenapanor Hcl | 11 | $32,699 |
| LokelmaSodium Zirconium Cyclosilicate | 26 | $25,080 |
| RenvelaSevelamer Carbonate | 11 | $17,384 |
| ProcritEpoetin Alfa | 13 | $13,385 |
| Sevelamer Carbonate | 33 | $8,435 |
| Potassium Citrate ErPotassium Citrate | 60 | $7,633 |
| Calcium Acetate | 66 | $3,712 |
| Midodrine Hcl | 18 | $2,885 |
| Torsemide | 154 | $2,874 |
| Omega-3 Acid Ethyl Esters | 20 | $1,040 |
| Allopurinol | 80 | $936 |
| Amiloride Hcl | 35 | $839 |
| Eplerenone | 11 | $801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $179 | $54,11924 claims |
| AstraZenecaLokelma | $609 | $25,08026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 nephrology providers in Pennsylvania.
Other nephrology in Philadelphia
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Ellie KelepourisPhiladelphia$287K
- Abdallahsassine GearaPhiladelphia$225K
- Katalin SusztakPhiladelphia$192K
- Debbie Cohen SteinPhiladelphia$112K
- Laura DemberPhiladelphia$110K
- Jonathan HoganPhiladelphia$100K
- Michael YoslovPhiladelphia$79K
- Michael LevinPhiladelphia$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.